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AbstrACt
Introduction Gabapentin is currently used ‘off-label’ in 
children and adolescents with chronic neuropathic pain, 
and reliable evidence of its effects and optimal dosing are 
lacking.
Objectives The GABA-1 trial aims to compare the efficacy 
and safety of gabapentin liquid formulation relative to 
tramadol and to explore the pharmacokinetics of both 
drugs in the treatment of chronic, neuropathic or mixed 
pain in the paediatric population.
Methods and analysis The trial is a multicentre, double-
blind, double-dummy, randomised, active-controlled, 
non-inferiority trial. Participants aged from 3 months to 
<18 years of age with moderate to severe (≥4/10 in age-
appropriate pain scales) chronic neuropathic or mixed 
pain will be recruited in 14 clinical sites in eight European 
countries. A total of 94 subjects will be randomised to 
receive gabapentin and tramadol placebo or tramadol and 
gabapentin placebo throughout 16–19 weeks (including 
3 weeks of titration [optimisation period], 12 weeks of 
treatment at a stable dose [maintenance period] and 1–4 
weeks of tapering [discontinuation period]). The primary 
objective is to assess the efficacy of gabapentin relative to 
tramadol for the treatment of moderate to severe chronic 
neuropathic or mixed pain by comparing the difference 
in average pain scores (assessed by age-appropriate 
pain scales) between intervention arms after 15 weeks of 
treatment. Secondary objectives include the assessment 
of the safety, quality of life and global satisfaction with 
treatment and the description of the pharmacokinetic–
pharmacodynamic relationship of gabapentin liquid 
formulation and tramadol oral drops to validate the 
recommended paediatric doses. Only rescue pain 
medication by paracetamol and/or ibuprofen is allowed 
during the trial.
Ethics and dissemination Ethic approval was obtained in 
the eight participating countries. Results will be submitted 
for publication in a peer-reviewed journal and presented at 
one or more scientific conferences.
trial registration numbers 2014-004851-30 and 
NCT02722603.
trial status Ongoing research study, currently recruiting.
IntrOduCtIOn
background
Neuropathic pain (NP) is caused by a lesion 
or disease of the somatosensory nervous 
system, but its physiopathology is frequently 
complex.1 In adults, prevalence of chronic 
pain with neuropathic features is estimated at 
3.3%–8.2%, and prognosis for recovery from 
strengths and limitations of this study
 ► This is the first clinical trial evaluating the efficacy 
of gabapentin for the management of chronic neu-
ropathic or mixed pain in children and adolescents.
 ► The trial is a multicentre, double-blind (participants 
and caregivers), double-dummy, randomised, ac-
tive-controlled, non-inferiority trial ensuring rigorous 
study design to assess drug effects.
 ► A newly developed oral liquid formulation of ga-
bapentin will be used, and the dosing regimen of 
gabapentin has been optimised using pharmacoki-
netic–pharmacodynamic modelling to bridge adult 
data to children.
 ► In contrast to standard efficacy trials in pain, data 
arising from this trial will be used in conjunction 
with modelling and simulation concepts to confirm 
the dose rationale for children from 3 months to 3 
years of age.
 ► As the rarity of the disease is a challenge to re-
cruitment, the participation of a large number of 
European centres (n=14) with paediatric pain exper-
tise was deemed necessary.
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NP is often poor.2 In children, there is growing evidence 
that prevalence is much lower, and that prognosis of NP 
in childhood differs from that seen when neural lesions 
occur in adulthood.3 This may be due to the higher plas-
ticity of the young nervous system that leads to a better 
restitution of function and lower incidence of pain than 
adults.4 5 Moreover, conditions with which NP is asso-
ciated differ between children and adults.3 6 Diabetic 
neuropathy (DNP) and postherpetic neuralgia (PHN) 
commonly related with NP in adults are rare in children. 
Established causes of NP in children include post-trau-
matic or postsurgery nerve injury, phantom limb pain, 
cancer and chemotherapy, genetic/metabolic diseases 
(eg, Fabry disease) and some chronic conditions and 
infections like HIV/AIDS that may cause nerve damage. 
Complex regional pain syndrome (type I and II) is a 
condition that occurs in both children and adults, and 
although largely debated, it is generally considered to 
comprise NP features.7 
Current guidelines for assessment and diagnosis of 
NP are designed for adults and thus may be less appli-
cable in children.1 8 Since there is no specific biomarker, 
clinical laboratory or functional test for NP, diagnosis is 
made merely on the basis of clinical symptoms. Hence, 
pain history is the mainstay of diagnosis and includes: 
evaluation of intensity; quality (sensory descriptors); 
temporal aspects of pain (frequency, spontaneous/parox-
ysmal or continuous, aggravating and relieving factors); 
and response to previous treatment (pharmacological 
or non-pharmacological). Physical examination should 
attempt to verify and locate the lesion of the somatosen-
sory system and document associated neurological signs, 
but this is often subject to the well-described challenges 
of pain assessment in young children. Sensory abnormal-
ities are also more difficult to elicit in infants and young 
children. Several tests can be indicated such as quanti-
tative sensory testing and electroneuromyography but 
are rarely performed in routine medical practice except 
to rule out other underlying pathology.3 Finally, assess-
ment of pain-related disability is important, and quality 
of sleep, mood and role functioning should be standard 
assessments for chronic pain conditions including NP.
In adults, drug therapy in NP is often unsatisfactory as 
the specific underlying mechanism is rarely well under-
stood.9 10 To date, in the absence of age-specific trials, 
guidelines for the management of NP in children have 
been developed exclusively based on data from clinical 
trials in adults.11 The analgesics that are most frequently 
prescribed for NP in children include tricyclic antide-
pressants (amitryptiline and nortriptyline) and gabapen-
tinoids (gabapentin and pregabalin).3 12 Opioids like 
tramadol have shown to be efficacious on NP in adults, but 
their use is often limited by their unfavourable benefit/
risk balance in chronic conditions.9 10 13 14
rationale
In adults, gabapentin has been shown to be effective in 
reducing neuropathic and mixed pain associated with 
DNP, PHN, multiple sclerosis and cancer-related pain 
and is marketed for the treatment of peripheral NP.9 15
In paediatric patients, reliable evidence of efficacy is 
lacking, and only case series reporting on the efficacy 
of gabapentin in treating chronic pain (always with a 
neuropathic component) are available.16–18 Although 
paediatric pain specialists have extensive experience 
with gabapentin off-label use for children, the potential 
benefits of gabapentin in treating chronic mixed and 
NP were never demonstrated in this population. Conse-
quently, the need for an adequately designed clinical 
efficacy/safety trial has been acknowledged as a means 
to ensure supporting evidence for current empirical 
clinical practice. In addition, this requirement has 
been specifically prioritised by the WHO Guideline 
Development Committee on the pharmacological 
treatment of persisting pain in children with medical 
illnesses.19 An additional constraint has been the way 
gabapentin is used off-label, as there is currently no 
marketed liquid formulation of gabapentin adequate 
for administration in infants and young children in 
Europe.
In this context, the Gabapentine in Paediatric Pain 
(GAPP) project is a European-funded project that 
comprises a full paediatric development programme 
for gabapentin in the treatment of chronic neuropathic 
or mixed pain in children.20 The development strategy, 
requirements and regulatory deliverables have been 
outlined in a paediatric investigation plan (PIP), which 
has agreed with and approved by the European Medi-
cines Agency’s (EMA) Paediatric Committee.21 The PIP 
includes: (1) the development of a liquid oral gabapentin 
formulation; (2) the evaluation of gabapentin safety in 
juvenile animal toxicity studies (PRE-GABA); (3) two clin-
ical trials to evaluate the efficacy and safety of gabapentin 
as monotherapy (GABA-1) and as adjuvant therapy 
(GABA-2); and (4) a modelling bridging study (GABA-3) 
to specifically address the paucity of pharmacokinetic 
(PK) data in children and enhance the dose rationale for 
the paediatric population.20 The study protocol presented 
in this paper concerns the GABA-1 trial.
ObjECtIvEs
Primary objective
The primary objective of the GABA-1 trial is to assess 
the efficacy of gabapentin relative to tramadol for the 
treatment of moderate to severe chronic neuropathic or 
mixed pain in children from 3 months to less than 18 
years of age by comparing the difference in average pain 
scores between intervention arms at the end of the treat-
ment period.
secondary objectives
1. To assess the effect of gabapentin relative to tramadol 
on quality of life (physical, emotional, social and school 
functioning) and global satisfaction with treatment.
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2. To assess the safety of gabapentin relative to tramadol 
for the treatment of chronic neuropathic or mixed 
pain in children 3 months to less than 18 years of age.
3. To characterise the population pharmacokinetic–
pharmacodynamic (PKPD) relationship of gabapentin 
liquid formulation and provide confirmation of the 
recommended paediatric dose.
Additional exploratory objectives of the trial include 
the following:
4. To describe the metabolomic profile following gab-
apentin and tramadol pain management treatments.
5. To explore genetic polymorphisms and their impact 
on PKs and pharmacodynamics (PDs) of both gab-
apentin and tramadol.
6. To assess the population PKs of tramadol and its PKPD 
relationship in the paediatric population.
MEthOds And AnAlysIs
GAbA-1 trial design and setting
This GABA-1 trial is designed as a randomised, double-
blind, double-dummy, active-controlled, parallel group, 
multicentre, non-inferiority trial. Tramadol was consid-
ered to be an adequate comparator to gabapentin in 
GABA-1 study because: (1) its efficacy in the management 
of NP has been shown in adults14 and opioids’ efficacy data 
from adults can be extrapolated to children,22 and (2) it 
is currently the only weak opioid marketed for children 
throughout Europe. The choice to conduct a non-infe-
riority trial was based on the fact that gabapentin is not 
thought to be necessarily more effective than tramadol 
for the treatment of neuropathic or mixed chronic pain 
in children; however, gabapentin may be better tolerated 
than tramadol.
Seven countries involving 14 academic paediatric 
hospital centres will be recruiting eligible children and 
adolescents (France: five centres; Italy: two centres; the 
Netherlands: two centres and Albania, Germany, Greece, 
Poland, UK with one centre each). In all of these hospitals, 
recruitment of potentially eligible patients will take place 
in specialised paediatric pain management units and in 
neurology, oncology, surgery and anaesthesia depart-
ments through local study promotion by the investiga-
tors. Patient enrolment begun in July 2018 (seven centres 
open to recruitment at that date) and is expected to end 
in 2019. Written informed consent will be obtained from 
parents and/or legal guardians as well as assent from all 
eligible patients prior to trial participation in accordance 
with applicable national laws and guidelines for enrol-
ment of children into clinical research. Informed consent 
and assent to take a blood sample for pharmacogenomics 
and metabolomic studies will be obtained separately. 
Informed consent and assent forms and age-tailored 
informative booklets are provided in online supplemen-
tary appendix 1.
A complete list of participating sites can be found on 
the  ClinicalTrials. gov site (https:// clinicaltrials. gov/ ct2/ 
show/ NCT02722603).
Eligibility criteria
Children and adolescents satisfying the following inclu-
sion criteria will be considered for participation to the 
GABA-1 trial:
1. Male or female, aged 3 months to less than 18 years at 
the screening visit.
2. Subjects that meet the diagnostic criteria for neuro-
pathic or mixed pain that is:
 – NP: ‘Pain arising as a direct consequence of a le-
sion or disease affecting the somatosensory system’. 
Subjects may present central or peripheral neuro-
pathic pain
 – Mixed pain: ‘Pain that has both a neuropathic and a 
nociceptive component’.
Since no validated tools exist to assess the presence 
of NP in children, diagnosis will be based on medical 
history (underlying disease, quality and temporal aspects 
of pain, plausible neurological distribution and response 
to previous treatment) clinical examination (positive and 
negative sensory criteria) and results of diagnostic tests.
Four criteria from the grading system for definition of 
NP will be considered2 23:
 – Pain distribution neuroanatomically plausible.
 – History that suggests relevant lesion or disease that 
affects the peripheral or central somatosensory system 
and with a temporal link between the lesion and 
disease causing the pain.
 – Clinical examination with demonstration of neurolog-
ical signs (negative or positive sensory signs with or 
without motor or autonomic signs) confined to inner-
vation territory of the lesioned nervous structure.
 – Diagnostic test confirming lesion or disease explaining 
NP: surgical or radiological confirmation of lesion (eg, 
MRI or CT confirming nerve compression), laboratory 
confirmation of disease (eg, metabolic disorder and 
multiple sclerosis (MS)), nerve biopsy confirmation of 
neuropathy and so on.
Patients under 3 years of age must meet at least one 
out of the four criteria and patients of 3 years of age and 
above must meet at least two out of the four criteria. To 
improve the diagnosis of neuropathic or mixed pain in 
children of less than 3 years of age, a list of genetic, meta-
bolic and neurodegenerative diseases that are specifically 
associated with occurrence of NP is also provided (online 
supplementary appendix 2).
For patients affected by CRPS type I: as diagnosis of this 
condition may not satisfy two out of four criteria of the 
Treede classification, the ‘Budapest’ diagnostic criteria 
as recommended for this condition by the International 
Association for the Study of Pain (IASP) will be used.24 25
3. Subjects that present with chronic pain defined as a 
recurrent or continuous pain persisting more than 3 
months.26 Duration of pain will be determined from 
the date of the first painful experience.
4. Subjects that present with at least moderate pain as de-
fined by an average pain intensity of ≥4/10 assessed 
during the 3-day screening period (ie, baseline assess-
ment period, where pain intensity is assessed two times 
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daily during 3 days; at least 5 out of the 6 pain intensity 
assessments must be available). Pain will be assessed us-
ing the following recommended pain scales according 
to age at the screening visit27:
 – Face, Legs, Activity, Cry, Consolability (FLACC) 
Scale in children aged 3 months to less than 3 years.
 – Faces Pain Scale – Revised (FPS-R) for children 
aged 3 years to less than 8 years; children in this age 
group that cannot perform self-assessment of pain 
intensity will use the FLACC Scale.
 – Pain Numeric Rating Scale (NRS-11) for children 
aged 8 years to less than 18 years.
5. Stable underlying disease and treatment.
6. In presence of malignant diseases, subjects in clinical 
remission and/or no expected changes in their ther-
apeutic protocol during participation to the present 
study.
7. Informed consent by parent(s) and/or legal guardian 
according to each country legal requirement.
8. Assent by the patient, where applicable, according to 
each country legal requirement.
Exclusion criteria include the following: pain dura-
tion ≥5 years; current use of gabapentin or tramadol 
or history of failure to respond to adequate treatment 
by gabapentin or tramadol/opioids for NP; history of 
epileptic condition except febrile seizure disorder; 
sleeping apnoea syndrome of any origin or subjects 
with history of severe respiratory impairment; sickle 
cell disease; significant cognitive impairment; current, 
controlled or uncontrolled, comorbid psychiatric diag-
nosis that can impair pain diagnosis and assessment such 
as severe depressive conditions or psychosis; history of 
suicidal ideation or behaviour; history of substance abuse 
in particular opioids; use of prohibited concomitant 
medication (detailed list is provided in online supple-
mentary appendix 3); current oral corticosteroid treat-
ment or corticosteroid infiltrations to treat pain caused 
by infiltration or compression of neural structures, for 
example, peripheral nerves or spinal cord; subjects born 
prematurely at ≤36 weeks’ gestational age if recruited 
during the first year of age; body mass index for age and 
gender of <5th percentile or >95th percentile glomerular 
filtration rate <90 mL/min/1.73 m2 (Schwarz equation); 
significant hepatic impairment or aspartate transaminase 
or alanine transaminase enzymes three times the upper 
limit of the age-specific reference range; known allergy, 
hypersensitivity or clinically significant intolerance to 
gabapentin or tramadol or any component found in the 
study drugs; subjects with fructose intolerance, diabetes, 
glucose-galactose malabsorption or lactase-isomaltase 
deficiency; clinically relevant abnormal ECG at the 
screening; surgery scheduled or in recovery from surgery 
occurring within 3 months of baseline assessment; female 
subjects who are pregnant or currently lactating; subjects 
who failed screening or were previously enrolled in this 
study; and participation in another clinical interven-
tional trial.
Intervention arms
The gabapentin oral liquid solution (syrup, 75 mg/mL, 
200 mL bottle) and both dummy placebos of gabapentin 
(syrup) and tramadol (oral drops) will be provided by 
Dompé Farmaceutici S.p.A (Milan, Italy). The tramadol 
oral liquid solution (oral drops, 100 mg/mL, 10 mL 
bottle) is marketed by EG S.p.A (Milan, Italy). Patients 
will be administered two investigational medicinal prod-
ucts (IMPs) (active product and placebo), orally, three 
times daily. To facilitate IMPs intake and increase compli-
ance, the dosing intervals will be flexible including a 
dose in the morning (before school), a dose in the after-
noon (after school) and one in the evening (bed time). 
A period of at least 4 hours should be observed between 
IMPs doses. Patients will be instructed only to use the 
provided devices (syringes) for the administration of the 
IMPs throughout the treatment period.
Selection of doses and dosing regimen
The doses to be used in this paediatric population were 
selected based on the results of a dose-optimisation 
approach using population PKPD modelling and simula-
tion to bridge adult data to children. A brief description 
of the approach is summarised below for both IMPs.
Gabapentin
Assuming that the exposure–analgesic response relation-
ship can be considered comparable between adults and 
children, a PK analysis was performed to evaluate the 
dosing requirements to ensure drug concentrations equiv-
alent to those observed and found to be therapeutically 
efficacious and safe in adults.28 29 Reported adult values 
show that gabapentin efficacy in NP is reached with doses 
between 900 mg/day and 3600 mg/day.30 Based on this 
range and taking into account interindividual variability 
in the pharmacokinetics of gabapentin, the median value 
obtained for area under the concentration versus time 
curve at steady state (area under the concentration-time 
curve [AUC0–8h]) in adults was selected as target exposure 
for the paediatric population. The gabapentin popula-
tion PK model proposed by Ouellet et al31 was adapted 
to account for the mechanisms of gabapentin disposition 
accounting for the role of known demographic and clin-
ical covariates. A range of doses and dosing regimens were 
then evaluated using clinical trial simulations to ensure 
comparable gabapentin exposure across the population, 
irrespective of differences in age or body weight. A dosing 
regimen based on weight bands was selected taking into 
account the proposed dosing frequency (three times 
daily) and rounding rules.
Tramadol
Using published tramadol PK and PKPD models, which 
have been developed to describe acute pain control in 
children,32 we have attempted to characterise the phar-
macokinetics across the overall paediatric population (3 
months to <18 years of age) and identify suitable titration 
steps for tramadol. Assuming that the exposure–response 
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relationships of tramadol do not differ significantly 
in acute and chronic pain conditions, the publication 
by Garrido et al33 was used to derive exposure values 
associated with the analgesic effect in the paediatric 
population. Similarly, comparable exposure–response 
relationships were assumed for toxicity, which has been 
previously shown to occur at varying blood concentra-
tions but all above 30.0 mg/L (range: 30–134 mg/L).34 
The population PK model published by Bressolle et al35 
was selected for the evaluation of a range of doses and 
dosing regimens that mimic those previously described 
for gabapentin. For all scenarios, tramadol was adminis-
tered according to a three times daily dosing regimen so 
that dosing intervals could be aligned with the regimen 
used for gabapentin.
Prohibited and authorised concomitant medications
The concomitant use of drugs that may interfere with the 
assessment of efficacy, safety or tolerability of both IMPs 
is prohibited during the entire study period and need to 
be discontinued before start of enrolment into the trial. 
The detailed list of drugs is given in online supplemen-
tary appendix 3.
All other concomitant pharmacological and non-phar-
macological medications implemented during the study 
must be reported by the patients in the patient’s diary and 
documented in the electronic case report form (eCRF). 
Although antacids containing aluminium and magnesium 
are not prohibited, they may interfere with gabapentin 
PK profile. For this reason, intake of gabapentin should 
occur at least 2 hours before or after taking antacids.
Non-pharmacological interventions for the manage-
ment of NP will be continued if initiated before inclusion 
to the protocol but should not be initiated during study 
period.
Rescue medications
Unrestricted use of paracetamol and/or ibuprofen will 
be used as rescue therapy if the patient experiences pain 
(FLACC, FPS-R or NRS-11 pain scale >4/10) at any time 
during study period. These medications will be used at 
standard therapeutic doses: paracetamol: 15 mg/kg, 
with a maximum of 1 g (oral or rectal), every 4–6 hours 
as necessary; maximum total daily dose is 60 mg/kg with 
a maximum of 4 g, divided into four doses; ibuprofen: 
5–10 mg/kg (oral or rectal) every 6–8 hours, oral doses 
can be taken with or after food; maximum total daily 
dose is 30 mg/kg/day divided into 3–4 doses. The inves-
tigator is the person responsible to instruct the parents/
participants on the use of paracetamol and/or ibuprofen 
as rescue medication and those instructions are to be 
reported in the patients’ diary. Use of comedication 
(dose and duration) must be carefully monitored in the 
patient diary.
Corticosteroids can be continued as part of the specific 
oncological treatment. However, systemic corticosteroids 
administered for pain caused by infiltration or compres-
sion of neural structures, for example, peripheral nerves 
or spinal cord, are not allowed.
trial procedures
Figure 1 summarises the design of the trial and visits 
described in detail below.
screening
On the first day of participation, following consent, 
screening assessment of patients for participation will be 
performed. The screening period will be of maximum 
7 days to allow for all screening results to be obtained and 
validated, in particular the assessment of the subject’s 
baseline pain intensity (mean over three consecutive 
days) prior to randomisation.
A wash-out period may be required if the subject is on an 
analgesic medication that could interfere with the baseline 
pain intensity assessment. The wash-out period must be at 
least five times the half-life of the medication. However, 
study wash-out period will be limited to a maximum of 
3 days. Subjects under medications that require a wash-out 
period of more than 3 days will be excluded unless these 
medications have been discontinued as part of usual 
Figure 1 Design of the trial. 
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medical care before inclusion to the protocol. During 
wash-out and screening period, rescue treatment will be 
allowed (ibuprofen or/and paracetamol).
randomisation
Random sequence generation
A computer random number generator (R+ script, block-
rand package) will be used to select random permuted 
blocks of randomly varying sizes for the generation of 
the two intervention arms. Patients will be individually 
randomised to receive either gabapentin 75 mg/mL 
syrup and a tramadol placebo, three times/day (experi-
mental group) or tramadol oral drops 100 mg/mL and 
a gabapentin placebo, three times/day for 15 weeks 
(control group) in an equal allocation ratio. Randomis-
ation will be stratified according to three age groups: 3 
months–<3 years; 3–<8 years and 8–<18 years. In addition, 
eligible patients will also be randomised for PK sampling 
purposes. Indeed, PK blood samples will be collected at 
one of three visits after the start of treatment namely, 14 
days±2 (V5), 21 days±2 (V6) or 105 days±3 (V10). All lists 
of randomisation will be created centrally at Erasmus 
Medical Centre, Rotterdam, the Netherlands.
Allocation concealment
Central web-based allocation will be used to conceal 
allocation. The treatment allocation scheme has already 
been created and has been integrated in the trial’s eCRF 
to ensure concealment of treatment allocation. Each 
patient will be given a unique study number on trial 
screening and then a unique randomisation number on 
randomisation. Patients will be randomly assigned when 
all eligibility criteria are entered and validated in the 
eCRF. Only the locally authorised investigators respon-
sible for recruitment will be able to randomise patients. 
Patients’ eligibility and randomisation will be confirmed 
by email sent from the eCRF server to the principal site 
investigator.
treatment period
Optimisation period
Dosing of both IMPs will initiate at a starting dose and will 
be titrated to response up to a maximum dose, according 
to a predefined matrix. Dosing for gabapentin is defined 
according to two weight groups from a starting dose of 
5 to 7 mg/kg/day to a maximum dose of 45 to 63 mg/
kg/day (table 1). By contrast, dosing of tramadol will be 
performed according to the following dosing schedule: 
starting dose (V2)=1 mg/kg/day; day 3±1 after start of 
IMPs (V3)=2 mg/kg/day; day 5±2 (V4)=3 mg/kg/day; day 
14±2 (V5)=5 mg/kg/day; day 21±2 (V6)=8 mg/kg/day. 
Maximum allowed daily dose of gabapentin and tramadol 
will be 3600 mg and 400 mg, respectively.
Titration to response will be flexibly optimised in order 
to maximise the potential benefits while minimising risk 
of AEs. There will be a maximum of five possible dose 
adjustments during the 3-weeks optimisation period. A 
dose will be indicated as optimal if the subject has reached 
a pain intensity of less than 4/10 in all pain assessments 
in the last 48 hours or the maximum tolerable dose. In 
that case, doses will not be further increased. If necessary, 
the investigator will be allowed to lower the subject’s dose 
level once (to the previous dose level) at any point during 
optimisation. This dose reduction may be followed by 
subsequent dose increases. Only one dose reduction will 
be allowed during optimisation period. Subjects who are 
unable to tolerate the IMPs after one dose reduction will 
be discontinued. When a dose adjustment is required, 
subjects will be asked to adjust the dosing of both IMPs 
(active and placebo IMPs). No dose adjustments can be 
made after V6 (day 21 after start of IMPs).
Maintenance period
Both IMPs will be maintained at the dose reached at the 
end of the titration phase for a total of 12 weeks. Dose 
adjustments will not be possible during maintenance 
period even if the maximum dose has not been reached 
during optimisation (last possible adjustment at V6).
Discontinuation period
All subjects who will have completed the study or who will 
have been withdrawn earlier must be tapered off from the 
IMPs to prevent withdrawal effects. At the visit of early 
termination or end of study (EOS visit; V10), subjects 
will be dispensed a blinded taper dose, and a tapering 
schedule will be determined based on the subject’s dose 
administered in the dose maintenance period (table 2).
During the taper period (if applicable), site staff 
will contact subjects every week to ensure that they are 
complying with the taper schedule and to remind subjects 
to start the next week of dose taper.
Parents and/or participants will be given instructions on 
how to keep a daily patient dairy to record the following 
items: daily pain score, study drug intake changes, come-
dication intake, including rescue medications and any 
adverse events.
Table 1 Dose optimisation schedule of gabapentin
Weight group V2 V3 V4 V5 V6
≤15 kg 7 mg/kg/day 14 mg/kg/day 21 mg/kg/day 42 mg/kg/day 63 mg/kg/day
>15 kg 5 mg/kg/day 10 mg/kg/day 15 mg/kg/day 30 mg/kg/day 45 mg/kg/day
IMPs, investigational medicinal products; V2, start of IMPs; V3, day 3±1 after start of IMPs; V4, day 5±2 after start of IMPs; V5, day 14±2 after 
start of IMPs; and V6, day 21±2 after start of IMPs.
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Overall, eight visits (V1, V2, V5, V6, V8, V9, V10 and 
V11) will be performed at the study site during the study 
period. Remaining visits (V3, V4, V7 and follow-up) will 
be conducted by phone. Supplementary visits at site can 
be performed at the discretion of the investigator during 
both optimisation and maintenance periods.
Outcome measures
Primary endpoint
Average pain score at the end of the treatment period 
(average of two measures each day for 3 days before EOS 
visit, V10) as assessed by age-appropriate pain scales:
 – FLACC Scale (observational assessment scale) in chil-
dren aged less than 3 years.36
 – FPS-R (self-assessment scale) for children aged 3 years 
to less than 8 years; children in this age group that 
cannot perform self-assessment of pain intensity will 
use the FLACC Scale.37 38
 – Pain NRS-11 (self-assessment scale) for children aged 8 
years to less than 18 years.27
Secondary efficacy endpoints
a. Percentage of responders to treatment defined as 
subjects with a reduction of 30% from baseline or 
equal to 3/10 of pain intensity assessed by appropri-
ate scale (FLACC, FPS-R and NRS-11) at the end of 
the study.
b. Daily pain intensity assessed by age appropriate scale 
(FLACC, FPS-R or NRS-11) during dose optimisa-
tion (V3–V6).
c. Observational assessment using the NRS-11 complet-
ed by parents and investigator (or caregiver) at each 
visit.
d. Self-assessment of pain for children ≥8 years of age 
using the FPS-R pain scale at each visit.
e. Extent of pain evaluated as the number of painful 
areas using the pain charts at screening visit (V1), 
randomisation (V2) and EOS visit (V10).
f. Number of episodes of breakthrough pain (>4/10 
pain score and use of rescue medications) during 
treatment period.
g. Number of rescue interventions required during 
treatment period.
h. Number of pain-free (<4/10 average pain score with-
out the use of rescue medications) days during treat-
ment period.
i. Number of participant dropouts due to lack of 
efficacy.
j. The total cumulative weight normalised dose of each 
rescue drug.
k. Quality of life, physical, emotional, social and school 
functioning and quality of sleep as assessed on 
the Paediatric Quality of Life Inventory (PedsQL) 
Generic Core Scales (by parent and patient)39 as-
sessed at randomisation (V2) and EOS visit (V10).
l. Acceptability of treatment (Five-Point Facial Hedonic 
Scale, by patient) at EOS visit (V10).
m. Global satisfaction with treatment (NRS-11, by par-
ent and patient) at EOS visit (V10).
n. Clinical Global Impression of Change (Clinical 
Global Impression – Severity scale (CGI-S) and 
Clinical Global Impression – Improvement scale 
(CGI-I); by investigator) at randomisation (V2) for 
CGI-S and V6 and EOS visit (V10) for CGI-I.40
o. Patient/parent Global Impression of Change (by 
parent and patient) at V6 and at EOS visit (V10).41
p. Assessment of blinding: guess of the subject’s treat-
ment group (by investigator, parents and subject if at 
adequate maturity level) at V10.
Secondary PK outcomes
q. Primary (Apparent Oral Clearance (CL/F), 
Apparent Volume of Distribution (Vd/F), apparent 
first-order absoption rate constant (Ka)) and sec-
ondary (AUC, maximum concentrations (Cmax), 
time to maximum concentration (Tmax), concen-
tration at steady state (Css) and minimum concen-
tration (Cmin)) PK parameters for gabapentin and 
tramadol. 
r. Systemic exposure to investigational products during 
maintenance period, as assessed by predicted steady-
state concentrations.
Secondary safety endpoints
s. Incidence of adverse events at all visits (V1–V12).
t. Percentage of subjects discontinuing the trial due to 
treatment-emergent adverse events.
u. Aggressive behaviour in children aged >6 years using 
the Retrospective-Modified Overt Aggression Scale 
at V2, V6 and EOS visit (V10).42
v. Suicidal ideation/behaviour in subjects aged 6 years 
and older using the Columbia – Suicide Severity 
Table 2 Tapering schedule of investigational medicinal products
Last maintenance dose Days* 1–7 Days* 8–14 Days* 15–21 Days* 22–28
V6 dose level V5 dose V4 dose V3 dose V2 dose
V5 dose level V4 dose V3 dose V2 dose –
V4 dose level V3 dose V2 dose – – 
V3 dose level V2 dose – – – 
V2 dose level – – – – 
*Days after the end of study visit (V10).
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Rating Scale scores before IMP (screening V1), V6 
and at the EOS visit (V10) and end of taper visit 
(V11).43
Secondary exploratory endpoints
w. Metabolomic profile at screening (V1) and at EOS 
visit (V10), in responders and non-responders.
x. PK or PD outcomes based on genetic variation.
All scales that will be implemented in the GABA-1 
trial are validated and recommended for use in infants, 
children and adolescents. All age-appropriate versions 
and the validated translations of the different scales 
are considered. For observational assessments, raters 
(including parent or caregiver and the investigator or 
study centre designee) observing the subject’s behav-
iour should be consistent throughout the study. Parents 
(or principal caregiver) and patients will be trained to 
adequately use these scales at the screening visit, and they 
will also be provided with an individual patient diary that 
includes instructions for use. Patients and/or parents 
(caregiver) will be instructed to measure their pain level 
twice a day for assessment of primary outcome, if possible 
always at the same time of the day, for example, in the 
morning and in evening, before going to bed. Outside 
these periods, they will be instructed to provide daily pain 
level at their convenience but preferably at the same time 
of the day and before drug administration. Outcomes will 
be assessed according to the schedule of trial assessments 
presented in table 3.
blinding
Patients, parents and caregivers (all those assessing 
outcomes) will be blinded to intervention assignment. 
Gabapentin or tramadol and respective placebos will be 
indistinguishable in appearance as to maintain the study 
blind. Also, labelling will not allow identification of the 
actual treatment. During the trial, blinding will be broken 
by the investigator in case of predefined emergency 
purposes, where knowledge of the blinded treatment 
could influence further patient care. Also, the sponsor’s 
safety contact will unblind case safety reports, as per regu-
latory requirements. Otherwise, study blinding will only 
be broken upon completion of statistical analysis.
sample size and rationale for non-inferiority
A sample size of 94 patients was planned on the basis of an 
expected average baseline pain score of 7 (SD=2),44 45 an 
expected average end of treatment pain scores of 6 in the 
tramadol and 5 in the gabapentin group,46 47 a one-sided 
alpha level of 2.5%, a power of 80%, a non-inferiority 
margin (Δ) of 0.75 and a dropout rate of 10%. This 
non-inferiority margin of 0.75 reflects published find-
ings of clinically important differences in pain scores of 
1 point among children with baseline pain of ≤5 points 
and of 2 points among children with baseline pain of 
≥6 points on 10-point scales.48 We chose the mean of 
these two results, a 1.5 point difference, as a clinically 
important difference for our population. In keeping with 
the literature, this clinically significant difference in pain 
scores was halved to produce a Δ of 0.75 for the margin 
of non-inferiority, which is taken as the maximum size of 
the effect considered clinically irrelevant.49 As a one-way 
analysis of covariance (ANCOVA) accounting for baseline 
pain scores and other covariates will be used for assess-
ment of the primary endpoint, this estimated sample size 
has been adjusted for a design factor of 1-ρ2, where ρ is 
an estimate of the correlation between baseline and EOS 
pain scores.50 Based on previous estimates, this correla-
tion was assumed to be 0.79.37
If the null hypothesis is rejected and non-inferiority of 
gabapentin is demonstrated, an analysis of the superiority 
of gabapentin on tramadol will be conducted using these 
data. Taking the same parameters as those cited for the 
non-inferiority hypothesis, the estimated power for the 
superiority study will exceed 95% with a sample size of 94.
A minimum number of subjects per age group have 
been defined in agreement with regulators: (1) at least 12 
subjects aged 3 months to less than 3 years; (2) at least 30 
subjects aged 3 years to less than 8 years and (3) at least 40 
subjects aged 8 years to less than 18 years. No maximum 
number of patients per age group is specified.
data collection
Electronic Data Capture system for GABA-1 trial is 
provided by Advice Pharma (Milan, Italy), a company 
specialised in the computer management of clinical 
trials and includes the eCRF and data management 
services. On completion of each visit, a study coordi-
nator specifically designed and trained for the study 
will record all requested data on a standardised eCRF. 
The investigator will be responsible for the accuracy of 
the data entered in the eCRF. Source documents and 
electronic health record data will be available to ensure 
the quality and integrity of all the data recorded in the 
eCRF. The eCRF will be available for review to desig-
nated sponsor representatives at each scheduled moni-
toring/audit visit.
Also, processing and storage conditions of biological 
specimens for PK, pharmacogenomics and metabolomics 
analysis are specified in the ‘Study manual’ prepared 
specifically for the GABA-1 trial. All samples of PK, 
pharmacogenomics and metabolomics will be shipped 
together from each participating clinical site to the 
Department of Pharmacology of the School of Pharmacy 
UCL, London, UK, at the end of the trial.
Adverse events
Safety aspects of the study will be closely monitored by site 
investigators, by the sponsor’s medical expert and by the 
independent Data Safety Monitoring Committee (DSMC), 
which receives blinded, and on request, unblinded data 
for its judgement. In addition, specific adverse events 
related to the use of gabapentin or tramadol will be 
closely monitoring during the entire study period.
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Potential risks related to gabapentin
Gabapentin has very few drug interactions but can 
produce dose-dependent dizziness and sedation, which 
are reduced by starting with lower dosages and titrating 
cautiously.51 Other common side effects of gabapentin 
that have been described both in adults and children 
include: somnolence, visual disturbances, ataxia and gait 
disturbance, asthenia, headache and peripheral oedema. 
Most may occur during the first few weeks of administra-
tion but resolve over time. Dizziness and visual distur-
bances may cause additional risk of trauma.
Also, gabapentin use in paediatric patients with epilepsy 
was associated with the occurrence of central nervous 
system-related adverse events.52–54 The most significant 
of these can be classified into the following categories: 
(1) emotional lability (primarily behavioural problems), 
(2) hostility, including aggressive behaviours, (3) thought 
disorder, including concentration problems and change 
in school performance and (4) hyperkinesia (primarily 
restlessness and hyperactivity). Most of these events were 
mild to moderate in intensity. As an antiepileptic drug, 
gabapentin has the potential for increased risk of suicidal 
thought or behaviour.
A common side effect of gabapentin use in adults and 
children with epileptic conditions was urinary inconti-
nence. Also, presence of hydroureter and hydronephrosis 
has been observed in rats taking high doses of gabapentin 
(unpublished data from the pre-GABA study, D6.1 ‘DRF 
Study Report’, submitted to the European Commission 
on 10 November 2014, available on request). For these 
reason, a renal ultrasound exam will be performed for 
the youngest subjects (<3 years of age) at the beginning 
and the end of the study period.
Potential risks related to tramadol
In both children and adults, use of tramadol has been 
associated with occurrence of dry mouth, nausea, consti-
pation, somnolence and dizziness.55 Most recently, 
tramadol has been associated with respiratory depression 
in relation to polymorphisms in the CYP2D6 activity.56 
To avoid occurrence of any respiratory adverse events in 
the GAPP-1 trial, it was decided that: (1) the study popu-
lation would not include patients who recently under-
went tonsillectomy or with history of sleeping apnoea 
syndrome or severe respiratory impairment; (2) tramadol 
will not be taken with other central nervous system or 
respiratory depressants; and (3) occurrence of excessive 
sleepiness, sedation and breathing abnormalities will 
be closely monitored during the trial to allow prompt 
discontinuation of the treatment if necessary. Parents will 
be instructed to use the University of Michigan Sedation 
Scale.57 If the level of sedation is ≥2, the next drug dose 
will not be administered and parents are to immediately 
contact the investigator/research site.
Of note, it is anticipated that slow titration will reduce 
the impact of ultrarapid metabolism.58 Such an unlikely 
event might then represent a potential concern after 
the second or third step of titration (2 or 3 mg/kg/day). 
In addition, to avoid any errors of administration of 
tramadol, site investigators will instruct and insure that 
parents have fully understood tramadol administration 
modalities before starting the treatment.
Rare cases of tramadol dependence have been described 
mainly in individuals with previous history of substance 
abuse.59 Therefore, subjects with previous history of drug 
abuse, in particular opioids, will be excluded from the 
study. Also, careful monitoring of drug accountability 
based on rigorous accounting of the pharmaceutical 
units provided by the hospital pharmacy and returned 
at each visit by the participant will be implemented. To 
avoid the occurrence of potential opioid-like withdrawal 
symptoms, tramadol doses will be tapered progressively 
over a period of 1–4 weeks according to the level of the 
maintenance dose.
removal or withdrawal of trial participants
A subject may withdraw from the study at any time and 
for any reason without prejudice to its future medical 
care by the physician or the institution. Subjects may 
be withdrawn from study drug treatment at any time at 
the discretion of the investigator for safety, behaviour, 
non-compliance with study procedures or administrative 
reasons. The reason for withdrawal must be recorded 
(medical record and eCRF). Reasons include but are not 
limited to the following: adverse event; protocol violation; 
consent withdrawal, lost to follow-up; lack of efficacy (effi-
cacy is defined as pain intensity of less than 4/10 in all pain 
assessments in the last 48 hours during the maintenance 
period); continuous use of rescue medication (defined 
as use of the maximum daily dose of paracetamol and/or 
ibuprofen for 12 days in a period of 15 continuous days 
during the maintenance period); response criteria not 
met (optimisation period only); and pregnancy.
Any interruption in treatment must be recorded. If IMP 
is discontinued, regardless of the reason, subjects will be 
asked to return any unused IMP and return to the study 
centre for final safety evaluations. Also, at least three docu-
mented attempts (including one written communication) 
will be made to contact any subject lost to follow-up at any 
time point prior to the last scheduled contact (office visit 
or telephone contact).
No patient who has been randomised and withdraws 
from the study for any reason will be replaced.
statistical analysis
Analysis of efficacy variables
According to the CONSORT 2010 Statement for Non-In-
feriority trials, endpoints will be analysed for the per-pro-
tocol (PP) and the intend-to-treat (ITT) populations.60 In 
our trial, the ITT population will consist of all randomised 
patients who received at least one dose of IMPs, based 
on their randomisation arm, regardless of the treatment 
actually received (modified ITT). The PP population will 
be based on the treatment actually received. All patients 
excluded from the analysis will be described. No interim 
analysis is planned.
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The primary analysis of efficacy will be conducted using 
ANCOVA with baseline average pain score as a covariate. 
Other covariates will include centre, treatment, age group 
and any baseline characteristics (weight, height, gender, 
pain diagnosis, pain severity, underlying disease, dura-
tion of pain and use of non-pharmacological treatment 
approaches) found to differ significantly between the two 
groups in univariate analysis. A second ANCOVA model 
including a treatment-centre interaction term will be 
used to assess consistency across sites. The secondary effi-
cacy endpoint of proxy pain as measured by a caregiver 
using a numeric ranking scale will also be assessed using 
ANCOVA with treatment group and baseline average 
proxy pain score as covariates. Non-inferiority will be 
assessed based on the two-sided CI approach.
Intergroup differences with regards to other secondary 
efficacy endpoints will be assessed by χ2 tests for cate-
gorical variables and two independent sample t-tests or 
Wilcoxon-Mann-Whitney tests for continuous variables.
Analysis of safety variables
The safety population will consist of all patients who 
received any IMP and will be based on the treatment actu-
ally received. Secondary safety endpoints including scores 
for quality of life, acceptability of treatment, quality of 
sleep, and the suicide assessment protocol will be assessed 
using ANCOVA with treatment group and baseline scores 
as covariates. Intergroup differences in the mean number 
of adverse events will be assessed using two independent 
sample t-tests or Wilcoxon-Mann-Whitney tests.
PK and PKPD analysis
The population PK analysis of gabapentin and tramadol 
will provide the time course and variability of drug 
concentrations in plasma and a covariate analysis will also 
be performed to explore the influence of relevant demo-
graphic factors. Non-linear mixed effects modelling will 
be performed using NONMEM (Icon Development Solu-
tion, Maryland, USA) and covariate search will be based 
on a two-step approach including forward selection and 
backward elimination of each covariate.61 The likelihood 
ratio test will be used for comparison of hierarchical 
models and goodness of fit will be assessed by graphical 
methods. All data manipulation, including graphical and 
statistical summaries will be implemented in R+ software.62
In the PKPD analysis, secondary PK parameters 
describing systemic exposure (AUC, Cmax and trough 
concentration (Cτ) will be derived and used subsequently 
to assess potential correlations with measures of efficacy. 
The latter include the pain scores assessed using age-ap-
propriate pains scales. Initially, linear and non-linear 
regression techniques will be used to establish the statis-
tical significance of the correlation between model-pre-
dicted estimates of drug exposure and measures of 
efficacy, as determined by linear interpolation of the area 
under the effect curve during the course of treatment, 
the maximum change from baseline at the start of treat-
ment (ΔEmax). The analysis will also take into account 
treatment and other demographic and clinical factors 
as potential covariates on the intercept and slope of the 
correlations.
Missing data
Efforts will be made to reduce the rate of missing data; 
however, if that occurs, multiple imputation methods 
will be implemented. A mixed model repeated measures 
approach will be conducted as a sensitivity analysis of the 
primary outcome.
Statistical analyses will be performed using the SAS 
V.9.3 software package for PC.
Patient and public involvement
The GAPP Patient Advisory Board (PAB) managed by 
the patient organisation Childhood Cancer International 
(the Netherlands) and composed of patient and family 
representatives, psychologists and researchers, ensured 
that patient and family views were clearly accounted for 
in the development of the study protocol and all patient 
and parents informative and consent/assent materials. A 
representative of the organisation assisted in all project 
general assemblies where trial design and outcome 
measures were presented and discussed. Another repre-
sentative was part of the GAPP Ethics Board that reviewed 
and advised on the study protocol from an ethical 
perspective. The PAB also provided input on the content 
and design of all materials, print and video and provided 
substantial revisions in an iterative review process together 
with the GAPP Communications Team. The PAB then set 
up focus groups with children and adolescents meeting 
many of the GABA-1 inclusion criteria in the Netherlands 
and Italy to provide direct patient input on these mate-
rials. Focus group results were synthesised in a final report 
and included in the final revision of these materials.
A layman report will be prepared and translated in 
different languages (covering all participating countries) 
at the end of GABA-1 trial with the aim to inform the 
participants and their parents on the results of the trial, 
as well as the general public.
Monitoring
The sponsor will perform a pre-study qualification visit 
(PSQV) to verify that all clinical sites fulfilled require-
ments for the participation to the GABA-1 trial with 
regards to their capacity to recruit eligible patients but 
also from a human and technical resources point of view. 
Taking into consideration all available information/
documents already collected by the sponsor, specifically 
mandated Clinical Research Assistants (CRAs) checked 
with the sites the compliance of technical tools and facil-
ities (eg, centrifuge, fridge, freezer, surgery, pharmacy 
and laboratory) and other requirements. Once the PSQV 
is successfully concluded and after arrival of the IMPs at 
site and completion of all regulatory procedures, the site 
initiation visit will be performed by the sponsor. There-
after, all sites will be monitored periodically for quality 
and regulatory compliance to the GABA-1 study protocol, 
 o
n
 24 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023296 on 20 February 2019. Downloaded from 
13Kaguelidou F, et al. BMJ Open 2019;9:e023296. doi:10.1136/bmjopen-2018-023296
Open access
International Conference for Harmonisation - Good Clin-
ical Practice (ICH-GCP) and regulatory requirements. 
All source documents will be reviewed with regards to 
completion of the eCRF, and IMPs accountability will be 
closely audited. The frequency is set at 5 weeks after first 
inclusion in the site, and then on average every 3 months, 
and in any case on sponsor’s request. The interval 
between monitoring visits may be shorter than stated 
above, depending on recruitment rate, quality issues, trial 
site compliance or other site-specific issues.
Ethics and dissemination
A body with consultative functions, the GAPP Ethics 
Board, formed by independent experts and patient 
representatives external to the project, with the necessary 
expertise and knowledge to assist and advise the Project 
Scientific Committee on all ethical aspects of the conduct 
of the trial. Also, ethics approval for the conduct of the 
GABA-1 trial was requested in each individual country 
according to national procedures. All participants will 
undergo a process of informed consent and will be aware 
that trial participation is strictly voluntary and that they 
have the right to withdraw at any time. An independent 
DSMC with extensive experience in either paediatric pain 
management or clinical study methodology and biostatis-
tics will regularly review trial data and make recommenda-
tions on the continuation, modification and termination 
of the trial to ensure participants’ safety. The Sponsor and 
Patient Advisory Board will guarantee subjects’ rights and 
protection against any commercial considerations and 
conflicts of interest. Insurance has been contracted by 
the sponsor to ensure post-trial care and compensation to 
those who suffer harm from trial participation.
The results of the GABA-1 trial will be presented at rele-
vant scientific conferences and meetings and submitted 
to a peer-reviewed medical journal. The results will also 
be included in the regulatory file for the request of a 
Pediatric-Use Marketing Authorization for the new liquid 
formulation of gabapentin at the EMA.
dIsCussIOn
Chronic pain is estimated to affect at least 15% of chil-
dren with underlying conditions and is often poorly 
recognised and treated.63 To date, opioids, non-steroid 
anti-inflammatory drugs, antidepressants and anticonvul-
sants are among the most commonly used medications to 
treat chronic pain, but very few of these are formulated 
or authorised for paediatric use. Gabapentin is a drug 
proven to be efficacious and safe in adults with NP and 
in children with epilepsy. However, only case series have 
reported on the efficacy of gabapentin in treating chronic 
pain with a neuropathic component in children and an 
adequate formulation for administration in the youngest 
is currently missing in Europe. Nevertheless, paediatric 
pain specialists have extensive and mostly reassuring 
experience with gabapentin ‘off-label’ use in children.
The GABA-1 trial represents a balance between meth-
odological excellence and the reality of chronic pain 
management in paediatrics. It was designed to provide 
reliable evidence for the use of a new liquid formulation 
of gabapentin in children presenting with moderate to 
severe chronic neuropathic or mixed pain. There is a 
notable paucity of clinical trials in children presenting 
with chronic pain, and the GABA-1 trial will be the first 
one in the field of paediatric neuropathic or mixed 
pain.11 In fact, the conduct of such trials faces numerous 
methodological and practical challenges even in adults.64 
Some of those, more specific in paediatrics, include: 
the absence of validated diagnostic criteria for NP, the 
choice of an adequate comparator, the complexity of 
the blinding procedure, the rarity of the condition and 
that of previous data to use for sample size calculations 
and the optimisation of dosing schemas and titration. We 
addressed these challenges by defining a core scientific 
steering committee that reviewed available literature and 
interacted thoroughly with partners and field experts. 
Hence, the trial will provide high-level evidence for the 
management of chronic neuropathic and mixed pain 
in infants, children and adolescents through the imple-
mentation of randomisation procedures consistent with 
Cochrane recommendations and the use of double-blind 
and standardised patient follow-up and data collection.
We also used an innovative approach taking into 
account PKPD concepts to determine dose rationale for 
IMPs, gabapentin and tramadol in children. Moreover, 
trial design, titration and maintenance periods have 
been defined using optimal design methods to ensure 
that all collected data will be highly informative. Most 
trials in pain research are empirical and do not involve a 
rational, evidence-based selection of the evaluated dosing 
regimens. Indeed, little or no focus is given to exposure 
levels, and PK data are often not collected in efficacy 
studies, ignoring PK variability as a potential source of 
variation in pain response anald adverse events. Finally, 
the international and multicentre aspect of this study will 
allow to obtain widely generalisable data.
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